From Our Partners
Monday, July 4, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Agentase Awarded DARPA Contract for In Vivo Nanoplatform

by Global Biodefense Staff
January 15, 2014

The U.S. Department of Defense has recently awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense: 

Agentase LLC, Pittsburgh, Pa., has been awarded an $11,206,720 cost contract. The work will support the Defense Advanced Research Project Agency (DARPA) In Vivo Nanoplatforms (IVN) program.

IVN seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness and infectious disease.

Work will be performed in Pittsburgh, Pa., (44.59 percent); Cambridge, Mass., (8.04 percent); Davis, Calif., (40.92 percent) and College Station, Texas, (6.45 percent).  The estimated completion date is April 14, 2015.  Fiscal 2013 research and development funds are being obligated at time of award.  The contracting activity is DARPA, Arlington, Va., (HR0011-14-C-0030).

In 2012, DARPA released tangent Broad Agency Announcements to support development of In vivo Nanoplatforms for Therapeutics (IVN:Tx) and In vivo Nanoplatforms for Diagnostics (IVN:Dx).

Source: Defense.gov, FBO.gov

From Our Partners
Tags: AwardsDARPANanotech

Related Posts

Influenza Research
Biodetection

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC